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ABSTRACT
Combination therapy drugs are considered a fundamental way to control malaria as it mimimizes the risk 
of emergence of resistance to the individual partner drugs. Consequently, this type of therapy constitutes 
a driving force for the discovery of new drugs with different modes of action, since this will provide 
options for combining different drugs to achieve the optimum antimalarial treatment. In this context, a 
2,3,8-trisubstitued quinoline compound was found in a high throughput screen (HTS) to show an excellent 
inhibition of P. falciparum NF54 (IC50 = 22 nM) and low cytotoxicity. We performed a detailed evaluation 
of the substituents to improve the metabolic stability and solubility liabilities of the original hit and 
identified derivatives with enhanced physicochemical and/or PK properties and that maintained biological 
activity. However the high potency was not retained on testing against drug resistant plasmodium strains.
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INTRODUCTION
Malaria is an endemic human disease caused by 
the parasite plasmodium which uses the female 
Anopheles mosquito as a vector for transmition. 
It was estimated that 212 million new cases of 
malaria appeared around the world in 2015 (WHO 
2016). Although malaria can be prevented and even 
cured, children under 5 still represent an extremely 
vulnerable group which is susceptible to infection 
and death. In addition, resistance to artemisin-
based combination therapies (WHO 2016), the 
best available treatment nowadays, continues to 
develop, requiring the discovery of new medicines 
to treat this life threatening infection. Despite these 
issues, global efforts between public and private 
sectors, academia and NGO’s (non-governamental 
organization) have been able to reduce the number 
of deaths and endemic regions. Because of that, 
since 2000, a 20% decline in the number of infected 
people and a 50% decline in deaths were observed 
along with 16% retraction of areas where this 
disease is present (WHO 2016).
From a historical point of view, the first reported 
example of an antimalarial agent was described in 
the 17th century, in the powder of a tree bark found 
in South America which, acording to folklore, 
was named cinchona after being used to treat the 
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Countess of Chinchon, Ana de Osorio in 1630 
(Foley and Tilley 1998). Even after understanding 
the benefits of the cinchona tree, it was still two 
centuries later in 1820, that the French researchers 
Caventou and Pelletier were able to isolate the 
alkaloid quinine (1) in its pure form, which was 
shown to be responsible for the theraupeutic 
properties of the crude tree bark (Delepine 
1951). Moreover, the chemical connectivity of 
this quinoline-containing compound started to be 
elucidated more deeply by the German chemist 
Paul Rabe in 1907 (Rabe 1907).
During World War II, demand for quinine 
(1) increased substantially, mainly after Java, a 
big supplier of quinine, fell under the control of 
the Japanese army and exports were stopped. In 
addition, synthetic efforts to prepare quinine (1), 
described initially by Rabe (Rabe and Kindler 
1918), followed by Proštenik (Proštenik and Prelog 
1943) and finally by Woodward (Woodward and 
Doering 1944, 1945), which was claimed to be 
the first formal synthesis (Smith and Williams 
2008, Seeman 2007, Kaufman and Rúveda 2005, 
Stork et al. 2001) were not economically viable. 
As a result, pressure to develop alternative drugs 
with antimalarial activity increased. Chemical 
companies located in Germany and US were 
key players in the 1940’s in the process to find 
synthetic compounds to treat malaria. Basically, all 
the compounds developed to kill the plasmodium 
parasite had a quinoline core. The first one was 
plasmoquine (2), which due to toxicity was replaced 
by primaquine (3) (Figure 1). In the same decade, 
chloroquine (4) started to be widely used, however, 
reports of resistance during the Vietnam War in the 
1960’s, led to the development of mefloquine (5), 
an effective anti-malarial drug for the next three 
decades. Again, subsequent reports of resistance 
and side effects narrowed its use. Even today, the 
quinoline core is still present in compounds in 
clinical trials such as ferroquine (6) and in approved 
drugs like amodiaquine (7) (Figure 1).
MATERIALS AND METHODS
THF was distilled from sodium/benzophenone. 
Dichloromethane (CH2Cl2) was distilled from 
CaH2. Anhydrous DMF (98%) was used as 
purchased. Acetonitrile was HPLC grade. All 
other aquired solvents and reagents were used 
Figure 1 - Compounds containing quinoline heterocycle with antimalarial activity.
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without further purification. Derivatives 15 and 
16 were synthesized from the known ketones 
isopropyldihydro-2H-pyran-4(3H)-one (Nitz et 
al. 2009) and 2,6-dimethyltetrahydropyran-4-one 
(Reddy et al. 2004) respectively. For analytical 
purposes, derivative 14 was converted in solid 
hydrochloride salt using HCl 1 M in Et2O solution. 
Compounds 18, 21 and 28 were also converted 
in hydrochloride salts with the same procedure, 
to be used in the biological assay. Flash column 
chromatography was conducted using silica gel 
(230−400 mesh) or aluminum oxide (activated, 
neutral, Brockmann I, ~150 mesh). Analytical 
thin-layer chromatography was performed on 
silica gel 60 F254 plates and the visualization was 
accomplished using UV light or phosphomolybdic 
acid followed by heating. 1H and proton-decoupled 
13C NMR spectra were recorded in CDCl3, CD3OD 
or DMSO-d6 in different magnetic fields as 
indicated. The chemical shifts (δ) are reported in 
ppm using tetramethylsilane (TMS) at 0.00 ppm 
or the solvent residual peak as an internal standard 
(7.26 ppm with CDCl3, 3.31 ppm with CD3OD and 
2.50 ppm with DMSO-d6 for 1H NMR spectra and 
77.0 ppm with CDCl3, 49.0 ppm with CD3OD and 
39.52 ppm with DMSO-d6 for 13C NMR spectra). 
Data are reported as follows: chemical shift, 
multiplicity (s = singlet, d = doublet, t = triplet, 
q = quartet, bs = broad singlet, dd = doublet of 
doublets, ddd = doublet of doublet of doublets, m 
= multiplet, a = aparent), coupling constant(s) in 
Hz, integration. High-resolution mass spectrometry 
(HRMS) was performed using the electrospray 
ionization (ESI) technique. The parent ions ([M + 
H]+ or [M + Na]+) are cited. 
EXPERIMENTAL
General procedure A1, reductive amination
To a solution of the ketone/aldehyde (0.4 mmol, 1 
eq) and amine (0.5 mmol, 1.3 eq) in dichloromethane 
(0.3 mL, 1.2 M) was added NaBH(AcO)3 (0.45 
mmol, 1.2 eq). The mixture was stirred overnight 
at room temperature under argon atmosphere. The 
reaction mixture was quenched by adding 0.5 M 
NaOH and stirred for 30 minutes. The product was 
extracted with dichloromethane and the organic 
layer was washed with brine and dried over MgSO4. 
It was filtered and the solvent was evaporated. The 
crude was purified by column chromatography on 
silica gel using CHCl3-MeOH (9:1, v/v) as eluent.
General procedure A2, reductive amination
A solution of aldehyde and amine was stirred in 
dichloromethane until the formation of the imine 
was confirmed by IR. Methanol and NaBH4 were 
then added to the solution and it was stirred over 
night. The reaction was quenched with aq. sat. 
NaHCO3 solution and stirred for 30min. It was 
extracted with dichloromethane and the combined 
organic layer were washed with brine and dried 
over MgSO4. It was filtered and the solvent was 
evaporated. The crude was purified by column 
chromatography on silica gel using CHCl3-MeOH 
(9:1, v/v) as eluent.
General procedure B, nucleophilic aromatic 
substitution
The aromatic halide (0.17 mmol) was dissolved 
in the cyclic amine (1 mL, 0.17 M). The mixture 
was heated to reflux until no more starting material 
was observed by TLC. The reaction mixture was 
concentrated in vacuo, taken in water and extracted 
with dichloromethane. The organic layers were 
washed with brine and dried over MgSO4. After 
filtration, the solvent was evaporated and the crude 
was purified by column chromatography on silica 
gel using CHCl3 as eluent.
General Procedure C, oxime synthesis (Niralwad 
et al. 2011)
A solution of aldehyde (1 mmol, 1.0 eq), 
hydroxylamine hydrochloride (1.5 mmol, 1.5 eq), 
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and sodium acetate (1.5 mmol, 1.5 eq) in ethanol 
(2.5 mL, 0.4 M) was stirred overnight at room 
temperature. After the completion of reaction as 
monitored by TLC, the solvent was evaporated 
and water was added. The mixture was extracted 
with dichloromethane, the combined organic layers 
were washed with brine, dried over MgSO4, filtered 
and concentrated to yield the pure product.
General procedure D, Oxime reduction
An access of Raney-Ni in water was washed with 
methanol and added to a solution of the oxime (0.2 
mmol, 1 eq) and ammonia (7M in methanol, 1.2 mL, 
43 eq) in methanol (4 mL, 0.05 M). The reaction 
vessel was flushed with hydrogen gas and stirred 
under hydrogen atmosphere until TLC confirmed 
consumption of starting material. The crude was 
filtered through a short silica plug, concentrated 
and purified by column chromatography on silica 




Figure 3 - route 2
Intermediate 8: General procedure C, from 
aldehyde 9, yield: quant. 
Intermediate 10: General procedure B, yield: 77%. 
Intermediate 11: General procedure D, yield: 83% 
Derivative 12: General procedure A1, yield: 75%. 
1H NMR (500 MHz, CDCl3) δ = 7.87 (s, 1H), 7.45 
(d, J = 7.9 Hz, 1H), 7.38 (d, J = 7.0 Hz, 1H), 7.12 
(at, J = 7.5 Hz, 1H), 3.98 (q, J = 13.7 Hz, 2H), 3.82 
- 3.76 (m, 1H), 3.73 (t, J = 6.4 Hz, 4H), 3.63 (td, J 
= 12.3, 2.1 Hz, 1H), 2.94 – 2.82 (m, 1H), 2.65 (s, 
3H), 2.03 - 1.94 (m, 4H), 1.89 - 1.78 (m, 2H), 1.34 
(ddd, J = 24.0, 12.3, 5.0 Hz, 1H), 1.25 (s, 5H), 1.19 
(s, 3H). 13C NMR (126 MHz, CDCl3), δ = 156.2, 
145.4, 137.5, 134.3, 129.0, 124.6, 123.6, 123.4, 
121.9, 72.2, 60.7, 50.8, 49.6, 48.5, 44.2, 33.7, 31.6, 
25.7, 22.6, 17.7. HRMS m/z: [M+H]+ calcd for 
C22H32N3O 354.2545, found 354.2532.
N-((8-methyl-2-(pyrrolidin-1-yl)quinolin-3-yl)
methyl)tetrahydro-2H-pyran-4-amine (14)
Figure 3 - route 1
Intermediate 13: General procedure A2, from 
aldehyde 9, yield: 84% 
Derivative 14: General procedure B, product 
crystallized as salt with 1M HCl in Et2O, yield: 68%. 
1H NMR (500 MHz, MeOD d4, hydrochloride 
salt) δ = 8.67 (s, 1 H), 7.79 (d, J = 7.9 Hz, 1 H), 
7.72 (d, J = 7.3 Hz, 1 H), 7.47 (at, J = 7.7 Hz, 1 
H), 4.72 (s, 2 H), 4.07 - 4.14 (m, 4 H), 4.03 (dd, 
J = 11.6, 4.4 Hz, 2 H), 3.65 (tt, J = 11.7, 4.2 Hz, 
1 H), 3.41 - 3.51 (m, 2 H), 3.25 - 3.29 (m, 2 H), 
2.68 (s, 3 H), 2.15 - 2.26 (m, 6 H), 1.83 (qd, J = 
12.2, 4.7 Hz, 2 H).13C NMR (126 MHz, MeOD d4, 
hydrochloride salt) δ = 151.8, 149.5, 136.5, 136.2, 
128.1, 127.2, 127.0, 122.0, 118.1, 67.0, 56.8, 53.0, 
46.3, 30.6, 26.6, 15.9. HRMS m/z: [M+H]+ calcd 




Figure 3 - route 2
Derivative 15: General procedure A1, from 
intermediate 11, yield: 54%. 1H NMR (500 MHz, 
CDCl3) δ = 7.87 (s, 1H), 7.46 (d, J = 7.9 Hz, 1H), 
7.38 (d, J = 6.9 Hz, 1H), 7.12 (at, J = 7.5 Hz, 1H), 
3.93 (s, 2H), 3.83 (td, J = 11.7, 2.2 Hz, 1H), 3.79 
- 3.71 (m, 5H), 3.47 - 3.36 (m, 1H), 3.13 - 3.04 
(m, 1H), 2.65 (s, 3H), 2.03 - 1.94 (m, 4H), 1.85 
- 1.74 (m, 2H), 1.66 - 1.60 (m, 1H), 1.57 - 1.48 
(m, 2H), 0.92 (d, J = 6.7 Hz, 3H), 0.86 (d, J = 6.8 
Hz, 3H). 13C NMR (126 MHz, CDCl3) δ = 156.1, 
145.5, 138.1, 134.3, 129.0, 124.6, 123.6, 123.3, 
121.9, 62.9, 50.3, 50.1, 49.5, 33.3, 32.5, 31.1, 25.7, 
18.6, 18.4, 17.7. HRMS m/z: [M+H]+ calcd for 




Figure 3 - route 2
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Derivative 16: General procedure A1, from 
intermediate 11, yield: 32%. 1H NMR (500 MHz, 
CDCl3) δ = 7.88 (s, 1H), 7.45 (t, J = 8.7 Hz, 1H), 
7.38 (d, J = 6.9 Hz, 1H), 7.12 (at, J = 7.5 Hz, 1H), 
3.98 – 3.84 (m, 2H), 3.93 (s, 2H), 3.74 (t, J = 6.6 
Hz, 4H), 3.10 – 3.04 (m, 1H), 2.65 (s, 3H), 2.05 – 
1.93 (m, 4H), 1.64 – 1.55 (m, 2H), 1.46 – 1.34 (m, 
2H), 1.15 (d, J = 6.2 Hz, 6H). 13C NMR (126 MHz, 
CDCl3) δ = 156.2, 145.5, 137.9, 134.3, 129.0, 
124.6, 123.7, 123.3, 121.9, 67.9, 51.1, 50.1, 49.5, 
37.9, 25.7, 22.1, 17.7. HRMS m/z: [M+H]+ calcd 
for C22H32N3O 354.2545, found 354.2531.
1-methyl-N-((8-methyl-2-(pyrrolidin-1-yl)
quinolin-3-yl)methyl)piperidin-4-amine (18)
Figure 3 - route 1
Intermediate 17: General procedure A2, yield: 
quant.
Derivative 18: General procedure B, from 
intermediate 17 yield: 13%. 1H NMR (500 MHz, 
CDCl3) δ =  7.89 (s, 1H), 7.48 (d, J = 7.9 Hz, 1H), 
7.40 (d, J = 6.9 Hz, 1H), 7.14 (at, J = 7.5 Hz, 1H), 
3.99 (s, 2H), 3.75 (t, J = 6.5 Hz, 4H), 2.83 (d, J 
= 11.4 Hz, 2H), 2.67 (s, 3H), 2.55-2.47 (m, 1H), 
2.28 (s, 3H), 2.05 - 1.96 (m, 6H), 1.92 (ad, J = 12.1 
Hz, 2H), 1.54 -1.46 (m, 2H).13C NMR (126 MHz, 
CDCl3) δ = 156.2, 145.4, 137.6, 134.3, 128.9, 
124.6, 123.7, 123.4, 121.9, 54.5, 53.9,  49.5, 48.9, 
46.2, 32.8, 25.7, 17.7. HRMS m/z: [M+H]+ calcd 
for C21H31N4 339.2543, found 339.2535.
2,2,6,6-tetramethyl-N-((8-methyl-2-(pyrrolidin-1-
yl)quinolin-3-yl)methyl)piperidin-4-amine (20)
Figure 3 - route 1
Intermediate 19: General procedure A2, yield: 
quant.
Derivative 20: General procedure B, from 
intermediate 19, yield: quant. 1H NMR (500 MHz, 
CDCl3) δ = 7.88 (s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 
7.38 (d, J = 6.9 Hz, 1H), 7.12 (at, J = 7.5 Hz, 1H), 
3.98 (s, 2H), 3.71 (t, J = 6.4 Hz, 4H), 3.06 – 2.97 
(m, 1H), 2.64 (s, 3H), 1.98 (t, J = 6.5 Hz, 4H), 1.93 
(dd, J = 13.5, 2.8 Hz, 2H), 1.69 (s, 6H), 1.63 (t, J = 
12.5 Hz, 2H), 1.48 (s, 6H). 13C NMR (126 MHz, 
CDCl3), δ = 156.1, 145.5, 137.8, 134.3, 129.1, 
124.7, 123.4, 123.1, 122.0, 57.5, 49.7, 48.7, 47.8, 
42.9, 30.9, 25.8, 25.7, 17.7. HRMS m/z: [M+H]+ 
calcd for C24H37N4 381.3013, found 381.3004.
3,3-dimethyl-N-((8-methyl-2-(pyrrolidin-1-yl)
quinolin-3-yl)methyl)cyclohexanamine (21)
Figure 3 - route 2
Derivative 21: General procedure A1, from 
intermediate 11, yield: 80%. 1H NMR (500 MHz, 
CDCl3) δ = 7.87 (s, 1H), 7.45 (d, J = 7.9 Hz, 1H), 
7.37 (d, J = 6.9 Hz, 1H), 7.15 – 7.07 (m, 1H), 4.03 
– 3.90 (m, 2H), 3.75 - 3.71 (m, 4H), 2.70 – 2.60 (m, 
1H), 2.64 (s, 3H), 2.03 – 1.94 (m, 4H), 1.69 – 1.57 
(m, 2H), 1.49 – 1.37 (m, 2H), 1.32 – 1.36 (m, 1H), 
1.11 (td, J = 13.4, 4.1 Hz, 1H), 1.03 – 0.95 (m, 2H), 
0.94 (d, J = 5.0 Hz, 3H), 0.89 (s, 3H). 13C NMR 
(126 MHz, CDCl3), δ = 156.2, 145.4, 137.5, 134.2, 
128.8, 124.6, 124.0, 123.4, 121.8, 53.2, 49.5, 49.1, 
46.9, 39.0, 33.8, 33.3, 31.4, 25.7, 25.2, 21.4, 17.7. 





Figure 3 - route 2
Derivative 22: General procedure A1, from 
intermediate 11, yield: 56%. 1H NMR (500 MHz, 
CDCl3) δ = 7.88 (s, 1 H), 7.46 (d, J = 7.9 Hz, 1 
H), 7.38 (d, J = 6.9 Hz, 1 H), 7.12 (at, J = 7.5 Hz, 
1 H), 4.04 (d, J = 14.0 Hz, 1 H), 3.87 - 4.01 (m, 2 
H), 3.85 (d, J = 14.0 Hz, 1 H), 3.66 - 3.78 (m, 5 
H), 3.17 (q, J = 5.1 Hz, 1 H), 2.65 (s, 3 H), 2.04-
2.10 (m, 1 H), 1.93 - 2.02 (m, 4 H), 1.84-1.91 (m, 
1 H), 1.25 (d, J = 6.6 Hz, 1 H), 1.22 (d, J = 6.4 Hz, 
3 H). 13C NMR (126 MHz, CDCl3), δ = 156.2, 
145.4, 137.6, 134.3, 129.0, 124.6, 123.4, 123.3, 
122.0, 77.1, 65.7, 59.5, 50.1, 49.5, 32.1, 25.6, 17.7, 




Figure 3 - route 2
An Acad Bras Cienc (2018) 90 (1 Suppl. 2)
1220 PABLO D.G. MARTINEZ et al.
Intermediate 23: General procedure A1, from 
aldehyde 9, yield: 83% 
Derivative 24: General procedure B, yield: 88%. 
1H NMR (500 MHz, CDCl3) δ = 7.81 (s, 1 H), 
7.44 (d, J = 7.9 Hz, 1 H), 7.37 (d, J = 6.9 Hz, 1 H), 
7.09 (at, J = 7.5 Hz, 1 H), 3.76 - 3.84 (m, 4 H), 3.63 
(s, 2 H), 2.63 (s, 3 H), 2.47 (br, 8 H), 2.29 (s, 3 H), 
1.91 - 2.00 (m, 4 H). 13C NMR (126 MHz, CDCl3), 
δ = ppm 156.3, 145.7, 139.3, 134.0, 129.0, 124.7, 
122.8, 121.5, 120.5, 60.6, 55.3, 52.9, 49.4, 46.0, 




Figure 3 - route 2
Intermediate 25: General procedure A2, from 
aldehyde 9, crude product submitted to next step 
without purification.
Derivative 26: General procedure B, yield: 45% 
over two steps. 1H NMR (500 MHz, CDCl3) δ = 
7.88 (s, 1 H), 7.46 (d, J = 7.8 Hz, 1 H), 7.38 (d, J 
= 7.0 Hz, 1 H), 7.12 (at, J = 7.5 Hz, 1 H), 4.00 (s, 
2 H), 3.66 - 3.72 (m, 4 H), 2.70 (t, J = 6.0 Hz, 2 
H), 2.64 (s, 3 H), 2.46 (t, J = 6.0 Hz, 2 H), 2.21 (s, 
6 H), 1.93 - 2.01 (m, 4 H).13C NMR (126 MHz, 
CDCl3), δ =156.2, 145.4, 137.7, 134.3, 128.9, 
124.7, 123.4, 122.9, 122.0, 58.7, 51.7, 49.5, 46.3, 
45.3, 25.6, 17.7. HRMS m/z: [M+H]+ calcd for 
C19H29N4 313.2387, found 313.2378.
3-methoxy-N-((8-methyl-2-(pyrrolidin-1-yl)
quinolin-3-yl)methyl)propan-1-amine (28)
Figure 3 - route 2
Intermediate 27: General procedure A2, from 
aldehyde 9, yield: quant.
Derivative 28: General procedure B, yield: 13%. 
1H NMR (400 MHz, CDCl3) δ = 7.85 (s, 1H), 
7.45 (d, J = 7.9 Hz, 1H), 7.37 (d, J = 7.0 Hz, 1H), 
7.18 – 7.05 (m, 1H), 3.95 (s, 2H), 3.79 – 3.65 (m, 
4H), 3.45 (t, J = 6.2 Hz, 2H), 3.32 (s, 3H), 2.72 
(t, J = 6.8 Hz, 2H), 2.65 (s, 3H), 2.07 – 1.93 (m, 
4H), 1.79 (p, J = 6.5 Hz, 2H). 13C NMR (101 MHz, 
CDCl3) δ = 156.2, 145.4, 137.6, 134.3, 128.9, 
124.7, 123.34, 123.32, 121.8, 71.3, 58.6, 52.0, 
49.5, 46.8, 30.0, 25.7, 17.7. HRMS m/z: [M+H]+ 




Figure 3 - route 2
Intermediate 29: General procedure B from oxime 
8, yield: 91% 
Intermediate 30: General procedure D, yield: 85%
Derivative 31: General procedure A1, yield: 21%. 
1H NMR (500 MHz, CDCl3) δ = 7.98 (s, 1H), 7.52 
(d, J = 7.9 Hz, 1H), 7.42 (d, J = 7.0 Hz, 1H), 7.26 - 
7.22 (m, 1H), 3.94 (q, J = 13.5 Hz, 2H), 3.79 (ddd, 
J = 12.0, 4.9, 1.8 Hz, 1H), 3.63 (td, J = 12.3, 2.2 
Hz, 1H), 3.32 - 3.23 (m, 4H), 2.84 (tt, J = 11.3, 4.1 
Hz, 1H), 2.71 (s, 3H), 1.84 (dddd, J = 18.7, 14.6, 
4.0, 2.0 Hz, 2H), 1.79 - 1.73 (m, 5H), 1.67 (dd, 
J = 11.2, 6.1 Hz, 2H), 1.34 (ddd, J = 23.9, 12.5, 
5.0 Hz, 1H), 1.26 (s, 4H), 1.18 (s, 3H). 13C NMR 
(126 MHz, CDCl3), δ = 160.3, 145.2, 137.3, 135.7, 
128.9, 127.5, 125.3, 124.8, 123.9, 72.3, 60.7, 
51.6, 50.7, 47.3, 44.2, 33.6, 31.7, 26.4, 24.8, 22.6, 




Figure 3 - route 2
Intermediate 32: General procedure B, from 
oxime 8, yield: 77%
Intermediate 33: General procedure D, yield: 91%
Derivative 34: General procedure A1, yield: 56%. 
1H NMR (500 MHz, CDCl3) δ = 8.03 (s, 1 H), 
7.54 (d, J = 7.9 Hz, 1 H), 7.45 (d, J = 7.0 Hz, 1 
H), 7.27 (at, J = 7.5 Hz, 1 H), 3.87 - 3.99 (m, 6 
H), 3.80 (ddd, J = 12.1, 4.9, 1.7 Hz, 1 H), 3.59 - 
3.69 (m, 1 H), 3.35 - 3.45 (m, 4 H), 2.88 (tt, J = 
11.3, 4.1 Hz, 1 H), 2.71 (s, 3 H), 1.79 - 1.92 (m, 
2 H), 1.65 (br, 2 H, NH + H2O), 1.29 - 1.39 (m, 1 
H), 1.22 - 1.29 (m, 4 H), 1.16 - 1.22 (m, 3 H). 13C 
NMR (126 MHz, CDCl3) δ =159.0, 145.1, 137.9, 
135.8, 129.1, 126.9, 125.4, 124.8, 124.3, 72.2, 
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67.1, 60.6, 50.9, 50.8, 47.0, 44.1, 33.6, 31.6, 22.6, 





Figure 3 - route 2
Intermediate 35: General procedure B, from 
oxime 8, yield: 89%
Intermediate 36: General procedure D, yield: 68%
Derivative 37: General procedure A1, yield: 57%. 
1H NMR (500 MHz, CDCl3) δ = 8.03 (s, 1 H), 
7.56 (d, J = 7.9 Hz, 1 H), 7.47 (d, J = 7.0 Hz, 1 H), 
7.25 - 7.32 (m, 1 H), 3.97 (q, J = 13.4 Hz, 2 H), 
3.79 - 3.87 (m, 1 H), 3.67 (td, J = 12.2, 2.1 Hz, 1 
H), 3.37 - 3.53 (m, 4 H), 2.89 (att, J = 11.3, 4.1 Hz, 
1 H), 2.73 (s, 3 H), 2.67 (br, 4 H), 2.42 (s, 3 H), 1.83 
- 1.93 (m, 2 H), 1.72 (br, 2 H, NH + H2O), 1.37 (qd, 
J = 12.1, 5.0 Hz, 1 H), 1.25 - 1.32 (m, 4 H), 1.22 
(s, 3 H). 13C NMR (126 MHz, CDCl3), δ = 159.2, 
145.1, 137.6, 135.8, 129.0, 127.0, 125.3, 124.7, 
124.1, 72.2, 60.7, 55.4, 50.8, 50.1, 47.1, 46.3, 44.1, 
33.6, 31.6, 22.6, 17.6. HRMS m/z: [M+H]+ calcd 
for C23H35N4O 383.2805, found 383.2796.
2,2-dimethyl-N-((8-methylquinolin-3-yl)methyl)
tetrahydro-2H-pyran-4-amine (39)
Intermediate 38: To the oxime 8 (77 mg) in 
methanol (4mL) was added 10% Pd/C (8 mg) and 
the reaction was purged with hydrogen gas and 
stirred under hydrogen atmosphere over night. 
After filtration through a short silica plug, the crude 
material was treated with 1M HCl in ether to obtain 
the product as salt. Yield: 98%
Derivative 39: General procedure A1, yield: 40%. 
1H NMR (250 MHz, CDCl3) δ = 8.91 (d, J = 2.1 
Hz, 1 H), 8.08 (d, J = 2.2 Hz, 1 H), 7.65 (d, J = 7.9 
Hz, 1 H), 7.54 (d, J = 6.6 Hz, 1 H), 7.43 (at, J = 7.7 
Hz, 1 H), 4.04 (s, 2 H), 3.74 - 3.88 (m, 1 H), 3.64 
(td, J = 12.2, 2.2 Hz, 1 H), 2.93 (tt, J = 11.3, 4.1 
Hz, 1 H), 2.82 (s, 3 H), 1.78 - 1.97 (m, 2 H), 1.51 
(br, 3 H, NH + H2O), 1.28 - 1.45 (m, 2 H), 1.26 (s, 
3 H), 1.19 (s, 3 H). HRMS m/z: [M+H]+ calcd for 
C18H25N2O 285.1967, found 285.1956.
3-(((2,2-dimethyltetrahydro-2H-pyran-4-yl)amino)
methyl)-N,8-dimethylquinolin-2-amine (43)
Intermediate 40: A solution of aldehyde 9 (50 mg, 
0.24 mmol) and methylamine (40% in water, 0.21 
mL, 0.24 mmol) in dioxane (1.5 mL) was heated 
in a microwave oven for 10min at 120°C followed 
by 45min at 100°C. The solvent was evaporated 
and the crude stirred in THF/1 M HCl (1:1) for 
1h. After evaporation of volatiles the residue was 
neutralized with aq. sat. NaHCO3 and extracted 
with dichloromethane. The combined organic 
layers were washed with brine, dried over MgSO4, 
filtered and concentrated. The crude product was 
purified by chromatography over silica gel with 
Hexanes-Ethyl acetate (99:1, v/v) to yield: 87%.
Intermediate 41: General procedure C, yield: 
quant.
Intermediate 42: General procedure D, yield: 36%
Derivative 43: General procedure A1, yield: 
25%. 1H NMR (500 MHz, CDCl3) δ = 7.55 (s, 
1H), 7.41 – 7.36 (m, 2H), 7.13 (s, 1H), 7.08 (t, J 
= 7.5 Hz, 1H), 3.91 (s, 2H), 3.79 (ddd, J = 12.0, 
5.0, 1.6 Hz, 1H), 3.62 (td, J = 12.4, 2.2 Hz, 1H), 
3.12 (s, 3H), 2.83 (tt, J = 11.3, 4.0 Hz, 1H), 2.68 
(s, 3H), 1.92-1.88 (m, 1H), 1.86-1.83 (m, 1H), 1.33 
– 1.24 (m, 5H), 1.20 – 1.15 (m, 3H). 13C NMR 
(126 MHz, CDCl3), δ = 156.86, 146.40, 135.51, 
133.91, 129.14, 124.86, 122.73, 121.29, 121.02, 
60.69, 50.18, 49.31, 44.11, 33.59, 31.67, 27.93, 
22.52, 17.81, 0.04. HRMS m/z: [M+H]+ calcd for 
C19H28N3O 314.2232, found 314.2228.
3-(((2,2-dimethyltetrahydro-2H-pyran-4-yl)amino)
methyl)-N,N,8-trimethylquinolin-2-amine (49) 
Intermediate 44: To a solution of the 8-methyl-
2-(methylamino)quinoline-3-carbaldehyde (40) 
(184 mg, 0.96 mmol) and ethane-1,2-diol (0.23 
mL, 4.10 mmol) in toluene (1.5 mL), TsOH (16 
mg, 0.09 mmol) was added at room temperature. 
The mixture was refluxed until no more starting 
material was observed by TLC. The reaction was 
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allowed to reach room temperature and quenched 
by addition of 50 mL of water. After stirring for 
10 minutes, the crude was extracted with ethyl 
acetate. The combined organic layers were washed 
with brine and dried (MgSO4). The solvent was 
evaporated and the crude was purified by column 
chromatography on silica gel using Hexanes-Ethyl 
acetate (95:5, v/v) as eluent. Yield: 91%
Intermediate 45: A DMF suspension (2.5 mL) of 
compound 44 (214 mg, 0.88 mmol), 60% sodium 
hydride (53 mg, 1.31 mmol) and methyl iodide 
(0.066 mL, 1.00 mmol) was stirred for 2 hours at 
room temperature. Water was added to the reaction 
mixture and it was extracted with ethyl acetate. The 
organic layer was washed (sequentially with water 
and brine) and dried (MgSO4). The solvent was 
evaporated and the crude was purified by column 
chromatography on silica gel using Hexanes-Ethyl 
acetate (95:5, v/v) as eluent. Yield: 88%
Intermediate 46: A suspension of compound 45 
(167 mg, 0.17 mmol) in HCl 1M (3mL) was stirred 
at room temperature for 1 hour. The crude was 
neutralized with NaHCO3 aqueous and extracted 
with ethyl acetate, washed with brine and dried 
(MgSO4). The crude was used without further 
purification Yield: 95%
Intermediate 47: General procedure C, yield: 88%
Intermediate 48: General procedure D, yield: 81%
Derivative 49: General procedure A1, yield: 63%. 
1H NMR (500 MHz, CDCl3) δ = 8.01 (s, 1H), 7.51 
(d, J = 8.0 Hz, 1H), 7.42 (d, J = 7.0 Hz, 1H), 7.22 (t, 
J = 7.5 Hz, 1H), 4.02 – 3.92 (m, 2H), 3.83 – 3.76 (m, 
1H), 3.63 (td, J = 12.3, 2.0 Hz, 1H), 3.01 (s, 7H), 
2.87 (tt, J = 11.4, 4.1 Hz, 1H), 2.71 (s, 3H), 1.85 
(ddd, J = 12.7, 3.8, 1.9 Hz, 2H), 1.51 (s, 1H), 1.34 
(ddd, J = 24.0, 12.4, 5.1 Hz, 1H), 1.29 – 1.22 (m, 
5H), 1.19 (s, 3H). 13C NMR (126 MHz, CDCl3), δ 
= 159.79, 144.93, 137.37, 135.30, 128.95, 126.42, 
124.88, 124.73, 123.45, 72.28, 60.74, 50.85, 47.43, 
44.22, 42.08, 33.71, 31.68, 22.62, 17.66. HRMS 




Intermediate 50: Commercially available 2-chloro-
3-quinolinecarboxaldehyde was submitted to 
general procedure C, yield: 85% 
Intermediate 51: General procedure B, yield: 85%
Intermediate 52: General procedure D, yield: 40%
Derivative 53: General procedure A1, yield: 92%. 
1H NMR (250 MHz, CDCl3) δ = 7.91 (s, 1 H), 7.72 
(d, J = 8.4 Hz, 1 H), 7.59 (d, J = 7.9 Hz, 1 H), 7.44 - 
7.55 (m, 1 H), 7.15 - 7.25 (m, 1 H), 3.87 - 4.07 (m, 
2 H), 3.52 - 3.87 (m, 6 H), 2.87 (tt, J = 11.3, 4.0 Hz, 
1 H), 1.90 - 2.07 (m, 4 H), 1.74 - 1.90 (m, 2 H), 1.53 
(br, 2 H, NH + H2O), 1.22 - 1.42 (m, 5 H), 1.18 (s, 3 
H). 13C NMR (63 MHz, CDCl3), δ = 157.4, 146.7, 
137.2, 128.9, 126.8, 126.3, 124.4, 123.8, 122.3, 
72.2, 60.7, 50.8, 49.7, 48.5, 44.2, 33.7, 31.6, 25.6, 





Intermediate 54: Commercially available 
2-chloro-7-methyl-3-quinolinecarboxaldehyde was 
submitted to general procedure C, crude product 
used in next step without purification. 
Intermediate 55: General procedure B, yield: 82%
Intermediate 56: General procedure D, yield: 98%
Derivative 57: General procedure A1, yield: 63%. 
1H NMR (500 MHz, CDCl3) δ = 7.86 (s, 1H), 7.53 
(s, 1H), 7.49 (d, J = 8.1 Hz, 1H), 7.05 (dd, J = 8.1, 
1.5 Hz, 1H), 3.95 (q, J = 13.8 Hz, 2H), 3.78 (ddd, 
J = 12.0, 5.0, 1.8 Hz, 1H), 3.69 (s, 4H), 3.65 – 3.58 
(m, 1H), 2.86 (tt, J = 11.4, 4.1 Hz, 1H), 2.47 (s, 
3H), 2.01 – 1.93 (m, 4H), 1.88 – 1.77 (m, 2H), 
1.39 – 1.21 (m, 2H), 1.24 (s, 3H), 1.18 (s, 3H). 13C 
NMR (126MHz, CDCl3) δ = 157.5, 146.8, 139.1, 
137.1, 126.4, 125.7, 124.5, 123.4, 121.8, 72.2, 
60.7, 50.8, 49.7, 48.6, 44.1, 33.7, 31.6, 25.6, 22.6, 
21.8. HRMS m/z: [M+H]+ calcd for C22H32N3O 
354.2545, found 354.2533.
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Intermediate 58: Commercially available 
2-chloro-6-methyl-3-quinolinecarboxaldehyde 
was submitted to general procedure C, yield: 57%
Intermediate 59: General procedure B, yield: 99%
Intermediate 60: General procedure D, yield: 93%
Derivative 61: General procedure A1, yield: 30%.  
1H NMR (250 MHz, CDCl3) δ = 7.83 (s, 1 H), 
7.63 (d, J = 8.4 Hz, 1 H), 7.29 - 7.40 (m, 2 H), 
3.87 - 4.02 (m, 2 H), 3.55 - 3.84 (m, 6 H), 2.85 (tt, 
J = 11.3, 4.1 Hz, 1 H), 2.44 (s, 3 H), 1.90 - 2.01 
(m, 4 H), 1.73 - 1.90 (m, 2 H), 1.54 (br, 2 H, NH + 
H2O), 1.20 - 1.43 (m, 5 H), 1.18 (s, 3 H). HRMS 





Intermediate 62: To the stirred solution of 2, 
8-dichloroquinoline (2.0 g, 10.10 mmol) in THF 
under Argon (20 mL), freshly prepared LDA (3.78 
g, 35.35 mmol) was added at -78 oC and the mixture 
was stirred for 2 h at the same temperature. Then, 
DMF (2.9 g, 40.40 mmol) was added to the reaction 
mixture and stirred for 2 h at -78 oC. The resulting 
reaction mixture was quenched with NH4Cl 
solution and extracted with ethyl acetate (3x20 
mL). The organics layers were washed with brine 
and concentrated. The concentrated product was 
purified through silica gel column chromatography 
using 10% ethyl acetate in pet ether to afford step1 
product (0.9 g, 39%) as pale yellow liquid.
Intermediate 64: General procedure A1, yield: 
47%.
Derivative 65: NaOtBu (0.3 g, 2.96 mmol) was 
added to stirred solution of step 2 product (0.4 g, 
1.18 mmol) and pyrrolidine (0.17 g, 2.36 mmol) 
in 1, 4-dioxane (10 mL) at room temperature 
and stirred for 5 h at 80 oC. Then, the reaction 
mixture was concentrated under reduced pressure 
to obtain a residue. The resulting residue was 
partitioned between EtOAc and water. The organic 
layer was washed with brine, dried over Na2SO4 
and concentrated. The concentrated product was 
purified through silica gel column chromatography 
using 5% methanol in dichloromentahne followed 
by preparative HPLC.Yield: 38% as off white solid.
1H NMR (400 MHz, DMSO-d6) = δ 8.77 (brs, 
1H), 8.22 (s, 1H), 7.77 (d, J = 8 Hz, 1H), 7.71 
(d, J = 8 Hz, 1H), 7.27-7.23 (m, 1H), 4.47 (brs, 
2H), 3.55-3.77 (m, 7H), 1.96-2.04 (m, 6H), 1.53-
1.38 (m, 2H), 1.21 (s, 3H), 1.19 (s, 3H). 13C NMR 
(100 MHz, DMSO-d6) δ = 156.2, 143.04, 139.92, 
130.38, 129.47, 126.96, 124.09, 122.83, 117.96, 
72.04, 59.38, 52.80, 50.28, 45.21, 31.74, 29.13, 
25.74, 22.16. HRMS m/z: [M+H]+ calcd for 
C21H29ClN3O 374.1999, found for 374.2100.
3-(((2,2-dimethyltetrahydro-2H-pyran-4-yl)amino)
methyl)-2-(pyrrolidin-1-yl)quinolin-8-ol (66)
To a stirred solution of compound 65 (50 mg, 
0.13mmol) in 1,4-dioxane (8 mL) was added 
NaOtBu (18 mg, 0.18mmol) and 10% sodium 
hydroxide solution (0.5 mL) at room temperature. 
Then, it was degassed for 5 minutes. tButyl Brett-
Phos (2.28 mg, 0.02mmol) was added at RT and 
again degassed for 5 minutes. Then, it was heated to 
100 oC for 16 h under sealed tube. After completion 
of the reaction, the reaction mixture was diluted 
with water (30 mL), extracted with ethyl acetate 
(2x50 mL). The resulting extracted ethyl acetate 
was dried over Na2SO4 and concentrated under 
vacuum. The resulting concentrated product was 
purified through prep-HPLC (0.1% HCOOH in 
acetonitrile). Yield: 21% as off white solid. 1H 
NMR (400 MHz, DMSO- d6) δ = 8.01 (s, 1H),7.18 
(d, 1H, J = 8 Hz), 7.14-7.10 (m, 1H ), 6.94 (d, 1H, 
J = 7.6 Hz), 4.05 (d, 2H, J = 4.8 Hz); 3.75-3.69 (m, 
6H), 2.78-2.92 (m, 1H), 2.06-2.02 (m, 4H), 1.94-
1.88 (m, 2H), 1.38-1.27 (m, 2H), 1.24 (s, 3H), 1.20 
(s, 3H). 
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Parasite reduction ratio assay
The intraerythrocytic P. falciparum growth 
inhibition by drugs was determined using a 
modification of the in vitro [3H]-hypoxanthine 
incorporation method and has been published 
previously (Sanz et al. 2012).
Malaria activity assay
The biological activities (IC50) of compounds were 
determined against the drug sensitive P. falciparum 
NF54 strain in vitro (Desjardins et al. 1979). 
Additional resistance studies were conducted using 
the same protocol against various field-derived 
resistant strains which are described in Tables IV-V.
Metabolic stability assay
In vitro intrinsic clearance (CLint) was assessed by 
substrate depletion upon incubation with human 
liver microsomes (HLM) and rat liver hepatocytes 
(Rat Heps). These assays, unless otherwise stated, 
were conducted in triplicate according to previously 
published procedure (Jones et al. 2017). Data are 
summarized in Tables I-III. 
RESULTS AND DISCUSSION
The current work had the objective to find a 
tractable lead which could be transformed into 
a long acting drug suitable for Single Exposure 
Radical Cure and Prophylaxis (Burrows et al. 2013) 
when administered in combination with other anti-
malarials. Similarly to a previous described series 
(Krake et al. 2017), the initial hit 12 was discovered 
through HTS (high throughput screening) and 
constitutes a trisubstituted quinoline with excellent 
anti-plasmodial activity (IC50 Pf NF54 = 22 nM). 
(Figure 2) Although this quinoline-based compound 
showed other interesting properties such as low 
cytotoxicity (IC50 THP1 > 50 µM; IC50 Hep G2 > 
10 µM), minimal hERG inhibition (IC50 hERG = 23 
µM) and good permeability in Caco2 cells (34 . 10-6 
cm/s at pH = 6.5), a high logD led to metabolically 
instability and low solubility. MetID studies in 
human and mouse liver microsomes revealed that 
the main metabolite resulted from oxidation of 
8-methyl substituent.
Regarding activity during the malaria life 
cycle, compound 12 acts only at the blood stage 
of the protozoan. The in vitro speed of killing was 
compared to known antimalarial drugs by means 
of a parasite reduction ration assay (Sanz et al. 
2012). A moderate rate of killing was observed for 
12 (Figure 2), which is uncommon for quinoline 
antimalarials and may indicate a different mode 
of action compared to marketed quinolines. It was 
also observed that this compound had significant 
loss in potency against the resistant strain Pf K1, 
which was a concern (Figure 2).
In view of this profile, our initial strategy was 
to reduce logD by removing hydrophobic moieties 
and introducing polar groups on the assumption 
this would lead to improved metabolic stability and 
solubility. We also hoped to increase activity against 
PfK1, and other resistant strains if necessary.
CHEMISTRY
For the synthesis of most analogs in this series 
(Figure 3), commercially available 9 was subjected 
to reductive amination with various amines, 
followed by aromatic nucleophilic substitution to 
form trissubsstituted quinolines (Route 1). In cases 
where R1 was introduced from a ketone, 9 was 
first converted into the oxime 8 and reduced to the 
corresponding amine using Raney-Ni, followed by 
reductive amination to form the desired final product 
(Route 2). Compound 39, a 3,8-dissubstituted 
derivative, without any group at the 2-position was 
prepared using Pd catalysed hydrogenolysis which 
reduced the oxime and cleaved the C-Cl bond in a 
one pot procedure.
8-chloro and 8-hydroxy derivatives 65 and 
66 were accessed from commercially available 
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starting material 63, which was formylated and 
then underwent a similar reductive amination and 
aromatic substitution sequence as described before. 
The hydroxyl group of 66 was introduced last via 
palladium catalyzed hydroxylation (Figure 4).
SAR ANALYSIS
In order to explore SARs against Plasmodium 
falciparum (NF54 strain), we first investigated 
modifications of the tetrahydropyran unit (Table 
I). By removing both gem-dimethyls at the carbon 
α-Oxygen, we prepared 14, a less lipophilic 
analogue with better metabolic stability in human 
microsomes, but inactive. Replacement of the gem-
dimethyl with a bulkier isopropyl group afforded 
15. Although we did not expect to improve logD, 
this modification was performed to explore the 
influence of steric hindrance at this position, but 
all properties were inferior to the original hit 12. 
Moving one of the tetrahydropyran methy groups 
around the ring in 16, resulted in a moderately 
active compound but proved to be deleterious for 
solubility. Replacement of the oxygen by nitrogen 
afforded compounds 18 and 20 that were more 
soluble as a consequence of the introduction of a 
basic centre, with substantially enhanced metabolic 
stability for the N-Me piperidine analogue 18, 
although its activity was reduced to the micromolar 
range. Evaluating the influence of a cyclohexane 
ring in comparison with tetrahydropyran, we 
synthesized quinoline 21, which displayed 
moderate potency (200 nM). Thus, reduced 
activity for nitrogen or carbon analogues of 12 
confirmed the importance of the oxygen in this part 
of the molecule for activity against plasmodium, 
possibly via a specific hydrogen bond with the 
target protein. However, reduction of ring size 
to the tetrahydrofuran analog 22 resulted in >50-
fold drop of activity. Reducing the length of the 
linker through the piperazine 24 led to a complete 
loss of potency, athough logD, clearance and 
solubility were much improved. Using an acyclic 
substituent with nitrogen or oxygen at the end 
of the chain (derivatives 26 and 28) significantly 
improved solubility for both analogues and the 
metabolic stability in human microsomes for the 
former, but none retained activity. Generally, we 
observed that modifications to the tetrahydropyran 
ring only impacted on solubility or clearance, with 
good metabolic stability for nitrogen-containing 
Figure 2 - Original Hit profile (left) and speed of killing plot (right) of viable parasites after treatment with antimalarial drugs and 
compound 12.
An Acad Bras Cienc (2018) 90 (1 Suppl. 2)
1226 PABLO D.G. MARTINEZ et al.
Figure 3 - General strategies for the synthesis of quinoline derivatives. Reagents and 
conditions: a) primary amine, CH2Cl2, then NaBH4, MeOH, 83%-quant.; b) pyrrolidine, 100 
°C, 13%-quant.; c) H2NOH.HCl, NaOAc, EtOH, quant.; d) amine, 100 °C, 77%-91%; e) 
Raney-Ni, NH3, MeOH, H2, 40%-91%; f) ketone, NaBH(OAc)3, CH2Cl2, 16%-92%; g) Pd/C, 
H2, MeOH, then HCl/Et2O, 98%; h) aq. NH2CH3, 1,4-dioxane, MW (microwave irradiation), 
10 min/120 °C, 45 min/160 °C, 75%; i) ethylene glycol, p-TsOH, toluene, reflux, 91%; j) CH3I, 
NaH, DMF (dimethylformamide), 0 °C, 88%; k) HCl 1M, rt, 95%.
Figure 4 - Synthesis of 8-chloro and 8-hydroxy analogues. Reagents and conditions: a) LDA 
(Lithium diisopropylamide), THF, DMF, -78°C, 39%; b) 2,2-dimethyltetrahydro-2H-pyran-4-
amine, NaBH(OAc)3, DCE (1,2-dichloroethane), 47%; c) pyrrolidine, NaOtBu, dioxane, 80°C, 
38%; d) Pd2(dba)3, NaOtBu, NaOH aq 10%, 
tBu Brett Phos [2-(Di-tert-butylphosphino)-2′,4′,6′- 
triisopropyl-3,6-dimethoxy-1,1′-biphenyl], 1,4-dioxane, 100°C, 21%.
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TABLE I 
Selected modifications at the tetrahydropyran fragment.
Solub = solubility in phosphate buffer solution (PBS); H Mics CLint = intrinsic human 
microsomal clearance; Rat Heps CLint = intrinsic rat hepatic clearance; ND = not determined.
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analogues. However these modifications did not 
show a positive effect on antiparasitic activity.
We next turned our attention to the substituent 
at the 2-position of the quinoline core (Table 
II). We observed that removal or replacement of 
the pyrrolidine ring was unsuccessful with the 
exception of piperidine 31 that led to an 8-fold 
decrease in activity. Rings with two heteroatoms, 
small acyclic amines or even hydrogen substantially 
improved solubility (compounds 34, 37, 39, 43, 
49). Although the pyrrolidine ring was essential for 
potency, the initial hit 12 with this fragment showed 
the higher clearance by human microsomes. Thus, 
all other substituents tested, afforded better stability 
particularly the unsubstituted derivative 39 which 
displayed by far the lowest intrinsic clearance for 
this sub-series, probably because its lower logD.
Then we focused on the effect of the 8-methyl 
substituent on antiparasitic activity and in vitro 
clearance by microsomes and hepatocytes (Table 
III). Replacement by hydrogen (derivative 53) led 
to a 60-fold drop in potency and moving the methyl 
group around the aromatic ring reduced activity 
even further (analogues 57, 61). However, it was 
possible to replace the methyl group with a chlorine 
(quinoline 65) and retain activity, but without 
improving the remaining properties. In compound 
66, a hydroxyl function was installed, which 
significantly lowered logD and improved solubility 
and metabolic stability while only reducing activity 
12-fold.
To ensure the series maintained activity 
against parasites resistant to historical antimalarial 
drugs, the most active compounds, the original hit 
TABLE II 
Influence of the 2-substituent at the quinoline heterocycle.
Solub = solubility in PBS; H Mics CLint = intrinsic human microsomal clearance; 
Rat Heps CLint = intrinsic rat hepatic clearance.
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12 and 65 were tested against eight drug-resistant 
Pf strains (Table IV).
We observed that activity did not decrease 
substantially against most strains, except for an 
aproximate 8-fold reduction against K1 for both 
compounds. These results indicated a concerning 
level of resistance for this series which led us to 
determine activity against K1 for the most potent 
compounds (Table V).
In the examples described in Table V, we 
observed the same trend as for quinolines 12 and 65 
with an 8-fold reduction in activity suggesting that 
resistance is inherent in this series which would be 
a barrier to further development.
CONCLUSIONS
After our systematic SAR analysis we were able 
to prepare the chlorinated analogue 65, with 
comparable potency (IC50 = 24 nM) to the hit 12. 
A thorough investigation of physicochemical and 
DMPK properties revealed low metabolic stability 
in human microsomes and rat hepatocytes as 
additional issue with this series. 
The quinoline heterocycle is an useful platform 
to find active drug candidates against the malaria 
parasite. Although very potent candidates can be 
found with this scaffold as observed in the history 
of antimalarial drugs (quinine, chloroquine and 
mefloquine for example) it is important also to 
verify the resistance levels on different Pf strains as 
the appearance of this effect is frequently observed. 
The series appears to have a different mode of 
action to other quinoline drugs, such as chloroquine 
and mefloquine, as illustrated by the series showing 
a slower rate of killing in the blood stage. Further 
studies to identify the mode of action are planned.
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